Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Closes on $22M Series C Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – 23andMe today said that it has closed on its Series C financing, raising more than $22 million.

New investor Johnson & Johnson Development Corp. participated in the round, which also included New Enterprise Associates and Google Ventures, the Mountain View, Calif.-based personal genetics testing firm said in a statement.

"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make healthcare research and healthcare delivery more efficient," Anne Wojcicki, CEO of 23andMe, said in a statement.

In June last year, the company received $2.6 million in a Series B investment from Google. It also invested $3.9 million into 23andMe in 2007 to help the company launch.

In addition, 23andMe said that it has a number of key positions open that it is looking to fill. A year ago, the firm laid off staff in response to the economy and to remain competitive.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.